Eli Lilly’s MDR-TB Partnership makes the case for IP’s role in accessible, sustainable healthcare

Eli Lilly has released details of its MDR-TB [multi-drug resistant tuberculosis] Partnership programme, under which it has transferred technology and knowhow relevant to its Cycloserine and Capreomycin treatments to pharmaceutical manufacturers in…

Unlock unlimited access to all IAM content